Your browser doesn't support javascript.
loading
Hydroxocobalamin Versus Methylene Blue for Vasoplegic Syndrome in Cardiothoracic Surgery: A Retrospective Cohort.
Furnish, Craig; Mueller, Scott W; Kiser, Tyree H; Dufficy, Lisa; Sullivan, Breandan; Beyer, Jacob T.
Afiliación
  • Furnish C; University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO.
  • Mueller SW; University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO.
  • Kiser TH; University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO.
  • Dufficy L; University of Colorado Hospital, Aurora, CO.
  • Sullivan B; University of Colorado School of Medicine, Aurora, CO.
  • Beyer JT; Denver Health Medical Center, Denver, CO. Electronic address: Jacob.Beyer@dhha.org.
J Cardiothorac Vasc Anesth ; 34(7): 1763-1770, 2020 Jul.
Article en En | MEDLINE | ID: mdl-32115360
OBJECTIVE: To compare methylene blue with hydroxocobalamin as a rescue therapy for vasoplegic syndrome. DESIGN: Retrospective cohort. SETTING: Academic medical center. PARTICIPANTS: Patients undergoing cardiothoracic surgery treated for vasoplegic syndrome. INTERVENTIONS: Thirty-five patients were treated with methylene blue (n = 16) or hydroxocobalamin (n = 19). MEASUREMENTS AND MAIN RESULTS: Mean arterial pressure, systemic vascular resistance, and vasopressor exposures were recorded before and after medication administration. Change in time-averaged norepinephrine equivalents in the hour after administration was the primary outcome. The average norepinephrine equivalent observed at baseline in this cohort was 0.347 µg/kg/min. Methylene blue patients had greater Acute Physiological Assessment and Chronic Health Evaluation II scores (29.8 v 22.2; p = 0.01) and trended toward greater European System for Cardiac Operative Risk Evaluation II values (26.8% v 15.1%; p = 0.07). Methylene blue and hydroxocobalamin were associated with increased mean arterial pressure and systemic vascular resistance 1 hour after administration (10.6 mmHg and 192 dyn*sec/cm5; p = 0.01 and p = 0.01, respectively; 11.8 mmHg and 254 dyn*sec/cm5; p = 0.002 and p = 0.015, respectively). Hemodynamic changes were not different between the rescue therapy groups (p = 0.79 and p = 0.53, respectively). No significant differences were observed within the 1-hour change in time-averaged norepinephrine equivalents for either agent or when methylene blue and hydroxocobalamin were compared (0.012 ± 0.218 µg/kg/min v -0.037 ± 0.027 µg/kg/min; p = 0.46, respectively). When compared with baseline time-averaged norepinephrine equivalent (0.326 ± 0.106 µg/kg/min), only hydroxocobalamin was associated with decreased vasopressor requirements at the 1-hour (0.255 ± 0.129 µg/kg/min; p = 0.03) and 4-hour time points (0.247 ± 0.180 µg/kg/min; p = 0.04) post-administration. CONCLUSION: Methylene blue and hydroxocobalamin increased mean arterial pressures and systemic vascular resistance without significantly decreasing time-averaged norepinephrine exposure in the hour after administration.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vasoplejía / Hidroxocobalamina Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Cardiothorac Vasc Anesth Asunto de la revista: ANESTESIOLOGIA / CARDIOLOGIA Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vasoplejía / Hidroxocobalamina Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Cardiothorac Vasc Anesth Asunto de la revista: ANESTESIOLOGIA / CARDIOLOGIA Año: 2020 Tipo del documento: Article